

Treatment Experienced

Boceprevir for Patients with Prior Failure to PEG + RIB PROVIDE

Vierling JM, et al. J Hepatol. 2013;Dec 19 [Epub ahead of print].

Boceprevir for Patients with Prior Failure to PEG + RIB

PROVIDE Study: Features

PROVIDE: Study Features

- N = 168 HCV-monoinfected, treatment-experienced patients
- Prior treatment failure to peginterferon + ribavirin
- Single arm, phase 3, multicenter, rollover study at 80 sites
- All with chronic HCV and genotype 1
- Mean Age = 53
- Genotype: GT1a = 68%; GT1b = 38%
- Race: 84% white; 13% black
- Fibrosis: 16% with Metavir F3 or F4
- Prior Response: Null (31%), Partial (51%), Relapse (17%)
- All retreated with Boceprevir + Peginterferon alfa-2b + Ribavirin

Drug Dosing

Boceprevir = 800 mg three times daily

Peginterferon alfa-2b = 1.5 µg/kg once weekly

Ribavirin = 600-1400 mg/day (based on weight)

Boceprevir for Patients with Prior Failure to PEG + RIB

PROVIDE Study: Treatment Regimens

Week 0 4 8 12 24 36 44 48

Patients who enrolled within 2 weeks after ending/completing previous treatment with PR

B44 Boceprevir

PR44 Peginterferon + Ribavirin

Patients who enrolled ≥ 2 weeks after ending/completing their previous treatment with PR


B44 Boceprevir

PR48 Peginterferon + Ribavirin

Lead In

Boceprevir for Patients with Prior Failure to PEG + RIB PROVIDE Study: Results

PROVIDE: SVR 24 by Prior Response (mITT)



SVR = Sustained Virologic Response; mITT = modified intent to treat analysis

Boceprevir for Patients with Prior Failure to PEG + RIB PROVIDE Study: Conclusions

Conclusions: “Re-treatment with boceprevir with peginterferon/ribavirin (BOC/PR) improved SVR rates in all patient subgroups, including those with prior null response.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.